Ask AI
Back Back
WCLC 2025 Frontline Lung Cancer Advances
Novel Frontline Maintenance Therapy Approaches and Targeted Therapies in Lung Cancers: Key Data From the 2025 World Conference on Lung Cancer

Released: February 16, 2026

John Heymach
John Heymach, MD, PhD
Solange Peters
Solange Peters, MD, PhD
Activity Information

Activity

Key Takeaways
  • Recent phase III and pivotal studies presented at WCLC 2025 highlight clinically meaningful survival gains across multiple lung cancer subtypes.
  • Maintenance strategies following chemoimmunotherapy are redefining the treatment paradigm in ES-SCLC.
  • Novel targeted therapies continue to expand frontline and later-line options for molecularly defined subsets of EGFR-mutated, HER2-mutated, and ROS1-positive NSCLC.

In this commentary, John Heymach, MD, PhD, and Solange Peters, MD, PhD, discuss several of the most notable studies presented at the 2025 World Conference on Lung Cancer (WCLC) as related to advances in frontline maintenance for extensive-stage small-cell lung cancer (ES-SCLC) and targeted therapies for non-small-cell lung cancer (NSCLC).

Frontline Maintenance in ES-SCLC: Current Treatment Paradigm

John Heymach, MD, PhD: Small-cell lung cancer most commonly presents as ES-SCLC or metastatic disease and, for more than 3 decades, was treated with platinum chemotherapy plus etoposide as the standard of care. Development of new treatment strategies for this disease was slow. However, a major shift occurred with the introduction of PD-L1 inhibitors, as demonstrated in the IMpower133 and CASPIAN trials, which established chemoimmunotherapy as a new frontline standard. These studies showed comparable outcomes, with median overall survival (OS) improving from approximately 10 months to over 12 months and hazard ratios between 0.7 and 0.8. Although this represented a clear advance in the field, the magnitude of benefit remained modest and underscored the need for further innovation.

Solange Peters, MD, PhD: Historically, attempts to improve outcomes through alternative maintenance strategies following induction therapy have been unsuccessful. However, recent data have begun to shift the paradigm.

IMforte Study: Lurbinectedin Plus Atezolizumab as Maintenance

Solange Peters, MD, PhD: One such data set that is changing clinical practice is the phase III IMforte trial evaluating the addition of lurbinectedin to atezolizumab maintenance therapy following induction with platinum-etoposide plus atezolizumab. This strategy was designed to address the rapid disease progression frequently observed shortly after completion of chemotherapy in ES-SCLC. The trial met both of its primary endpoints, demonstrating statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and OS. Median PFS was 5.4 months with lurbinectedin plus atezolizumab vs 2.1 months with atezolizumab alone (HR: 0.54; P <.0001). Median OS was 13.2 vs 10.6 months (HR: 0.73; P = .017). These results are particularly notable in a disease historically associated with minimal gains in survival for novel maintenance therapy combinations.

At the 2025 WCLC, we presented extended safety data for IMforte. Hematologic toxicity was anticipated given the safety profile of lurbinectedin, so some patients received prophylactic G-CSF. Thrombocytopenia, anemia, and neutropenia were observed at a higher rate in the experimental arm, particularly during the first 3 months of treatment, and febrile neutropenia occurred in a small proportion of patients (1.7%). Of importance, adverse events were largely manageable, concentrated early in treatment, and resulted in a low rate of treatment discontinuation (6.2%). These findings indicate that with appropriate monitoring and supportive care, patients can remain on therapy and derive sustained benefit. Based on these results, lurbinectedin plus atezolizumab has been approved in the United States and represents a new standard maintenance therapy option for ES-SCLC.

DeLLphi-303: Tarlatamab-Based Maintenance Strategies

John Heymach, MD, PhD: The DeLLphi-303 phase Ib study explored a different maintenance strategy, evaluating the DLL3-targeted bispecific T-cell engager tarlatamab in combination with either atezolizumab or durvalumab following frontline chemoimmunotherapy with a PD-L1 inhibitor. Although the study was not randomized, the survival outcomes were striking. Median OS reached 25.3 months in the atezolizumab arm and was not yet evaluable in the durvalumab arm, with a combined median OS of 25.3 months across both treatment groups. These results far exceed historical benchmarks in ES-SCLC, where median OS has typically remained near 10-12 months. Observing survival beyond 2 years in this population suggests a potentially transformative advance. Tarlatamab is currently approved in the second-line setting for ES-SCLC, but the magnitude of benefit observed in the maintenance setting supports further investigation in randomized trials. If confirmed, this approach may ultimately redefine expectations for long-term survival in ES-SCLC.

Targeted Treatment for NSCLC: Current Treatment Paradigm

Solange Peters, MD, PhD: The treatment landscape for advanced NSCLC has been reshaped by precision oncology. Comprehensive molecular testing has revealed that approximately one third to one half of patients harbor actionable genomic alterations, allowing targeted therapies to replace conventional chemoimmunotherapy in many cases. This evolution has led to the subdivision of NSCLC into multiple molecularly defined subgroups and has contributed to substantial population-level survival improvements over recent decades. Oncogenic drivers that were previously considered undruggable, including KRAS and HER2, now have effective targeted agents. The integration of broad next-generation sequencing, including RNA-based testing for gene rearrangements, has further expanded the pool of patients eligible for precision treatment strategies.

FLAURA2: Osimertinib Plus Chemotherapy in EGFR-Mutant NSCLC

Solange Peters, MD, PhD: Osimertinib remains the standard first-line therapy for patients with common EGFR mutations, including exon 19 deletions and exon 21 L858R mutations. Recent studies have explored escalation strategies aimed at improving outcomes beyond osimertinib monotherapy. The FLAURA2 trial compared osimertinib plus chemotherapy with osimertinib alone and demonstrated a PFS benefit with a hazard ratio of 0.62. Final OS data presented at the 2025 WCLC reported a statistically significant hazard ratio of 0.77, corresponding to an approximately 10-month improvement in survival (47.5 vs 37.6 months). Of note, the benefit was consistent across all evaluated subgroups, including patients with brain metastases and those with high-risk molecular features.

Given the magnitude and consistency of benefit, escalation with chemotherapy represents a new standard of care that should be discussed with all eligible patients. Although some individuals may decline chemotherapy, informed decision-making requires consideration of the demonstrated survival advantage. From a tolerability standpoint, the combination appears manageable and may be easier to administer than alternative treatment such as amivantamab, which is associated with higher rates of dermatologic and gastrointestinal toxicity.

Beamion LUNG-1: Zongertinib in HER2-Mutant NSCLC

Solange Peters, MD, PhD: HER2-activating mutations occur in approximately 2% to 3% of NSCLC cases and are most commonly exon 20 insertions. Earlier HER2-directed tyrosine kinase inhibitors were limited by off-target EGFR inhibition, resulting in suboptimal efficacy and significant toxicity. Zongertinib is a selective HER2 inhibitor that spares wild-type EGFR and has demonstrated robust activity with improved tolerability. It recently received FDA approval for the treatment of unresectable or metastatic nonsquamous NSCLC with HER2-activating mutations after prior systemic therapy based on high and durable response rates.

Data for the phase Ib Beamion LUNG-1 study presented at the 2025 WCLC highlighted meaningful central nervous system activity, with intracranial objective response rate of 41% observed in patients with baseline brain metastases (disease control rate: 83%). At the 2025 European Society of Medical Oncology meeting, frontline treatment with zongertinib resulted in an overall response rate (ORR) of 77%, supporting the use of zongertinib earlier in the treatment course and reinforcing the principle of deploying the most effective targeted therapy upfront.

ARROS-1: Zidesamtinib in ROS1-Positive NSCLC

Solange Peters, MD, PhD: ROS1-positive NSCLC represents a small but clinically important molecular subset of patients. The phase I/II ARROS-1 study demonstrated activity of the ROS1 inhibitor zidesamtinib across multiple lines of therapy, including previously untreated patients and heavily pretreated patients with prior exposure to other next-generation ROS1 inhibitors. In treatment-naive patients, ORR approached 90%, with durable systemic and intracranial responses. Even among patients who had received multiple prior ROS1 TKIs, clinically meaningful activity was maintained (ORR: 44%), including central nervous system efficacy. These findings further support the strategy of using potent, next-generation TKIs early in the disease course to maximize benefit and delay resistance.

Where These Regimens Fit Into the Treatment Paradigm

John Heymach, MD, PhD: Across both ES-SCLC and NSCLC, data presented at the 2025 WCLC highlight the impact of optimizing frontline and maintenance treatment strategies. Intensifying maintenance therapy in ES-SCLC and escalating frontline targeted approaches in molecularly defined NSCLC subgroups demonstrate how thoughtful treatment sequencing can translate into meaningful survival gains. As these strategies continue to evolve, integrating emerging evidence into clinical practice will be essential to improving outcomes for patients with lung cancer.

Your Thoughts
How are you currently approaching maintenance therapy in ES-SCLC or escalation strategies in molecularly driven NSCLC, and what factors most influence your frontline treatment decisions? Let us know by leaving a comment below.